Smart shirt tracks radiation side effects in cancer patients
NCT ID NCT04983199
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special smart shirt, called Hexoskin, can help monitor side effects in 100 patients receiving palliative radiotherapy for cancer that has spread. The shirt tracks heart rate, breathing, and activity levels. The goal is to see if it's practical to use and if it can help detect side effects early, so they can be treated sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Hexoskin Smart Shirt (wearable device)
- What this could lead to
- If successful, this could show that wearable technology helps doctors catch and treat radiotherapy side effects earlier, improving patient comfort.
- What could go wrong
- This is a small, early feasibility study, not a treatment trial. The smart shirt may not reliably detect side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cancer patients planned for palliative radiotherapy to metastatic disease.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Planned to receive palliative radiotherapy for pain * Known cancer diagnosis * Able to wear Hexoskin Medical Shirt * Ability to use and populate the mobile app (Zamplo) with or without assistance * ECOG: 0-3 * Willing to provide a list of analgesic (pain relief) medication * Willing to complete questionnaires * Life expectancy of at least 3 months Exclusion Criteria: * Receiving whole brain radiotherapy * Major cognitive or psychiatric impairments * Pregnant women * Allergies to: polyester, synthetic fibers * Patients with pacemakers or implantable cardioverter-defibrillator (ICD) * Patients on a Holter Monitor
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Sugar-Coated proteins on cancer cells
- Zapping a few growing tumors may keep breast cancer drugs working longer
- Can a platform trial match the right drug combo to each tumor?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can a new antibody outsmart advanced solid tumors?
- Tissue analysis may guide personalized cancer therapy